Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
Comín-Colet J, Manito N, Segovia-Cubero J, Delgado J, García Pinilla JM, Almenar L, Crespo-Leiro MG, Sionis A, Blasco T, Pascual-Figal D, Gonzalez-Vilchez F, Lambert-Rodríguez JL, Grau M, Bruguera J; LION-HEART Study Investigators. Comín-Colet J, et al. Among authors: blasco t. Eur J Heart Fail. 2018 Jul;20(7):1128-1136. doi: 10.1002/ejhf.1145. Epub 2018 Feb 6. Eur J Heart Fail. 2018. PMID: 29405611 Free article. Clinical Trial.
Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain.
Manito Lorite N, Rubio-Rodríguez D, González Costello J, Díez López C, Enjuanes Grau C, Segovia-Cubero J, Delgado Jimenez JF, Campo Sien C, Rubio-Terrés C, Comín-Colet J; LION-HEART study researchers; Additional researchers in the LION-HEART Group. Manito Lorite N, et al. Rev Esp Cardiol (Engl Ed). 2020 May;73(5):361-367. doi: 10.1016/j.rec.2019.06.020. Epub 2019 Dec 30. Rev Esp Cardiol (Engl Ed). 2020. PMID: 31899185 Clinical Trial. English, Spanish.
Twelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipients.
Manito N, Delgado JF, Crespo-Leiro MG, Arizón JM, Segovia J, González-Vílchez F, Mirabet S, Lage E, Pascual-Figal D, Díaz B, Palomo J, Rábago G, Sanz M, Blasco T, Roig E. Manito N, et al. Among authors: blasco t. World J Transplant. 2015 Dec 24;5(4):310-9. doi: 10.5500/wjt.v5.i4.310. World J Transplant. 2015. PMID: 26722659 Free PMC article.
Risk factors associated with moderate-to-severe renal dysfunction among heart transplant patients: results from the CAPRI study.
Delgado JF, Crespo-Leiro MG, Gómez-Sánchez MA, Paniagua MJ, González-Vílchez F, Vázquez de Prada JA, Fernández-Yáñez J, Pascual D, Almenar L, Martínez-Dolz L, Díaz B, Roig E, Segovia J, Arizón JM, Garrido I, Blasco T, López J, Brossa V, Manito N, Muñiz J. Delgado JF, et al. Among authors: blasco t. Clin Transplant. 2010 Sep-Oct;24(5):E194-200. doi: 10.1111/j.1399-0012.2010.01249.x. Clin Transplant. 2010. PMID: 20597926
Cancer Incidence in Heart Transplant Recipients With Previous Neoplasia History.
Delgado JF, Alonso-Pulpón L, Mirabet S, Almenar L, Villa FP, González-Vílchez F, Palomo J, Blasco T, Dolores García-Cosio M, González-Costello J, de la Fuente L, Rábago G, Lage E, Pascual D, Molina BD, Arizón JM, Muñiz J, Crespo-Leiro MG. Delgado JF, et al. Among authors: blasco t. Am J Transplant. 2016 May;16(5):1569-78. doi: 10.1111/ajt.13637. Epub 2016 Feb 3. Am J Transplant. 2016. PMID: 26613555 Free article.
Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?
Gonzalez-Vilchez F, Vazquez de Prada JA, Paniagua MJ, Gomez-Bueno M, Arizon JM, Almenar L, Roig E, Delgado J, Lambert JL, Perez-Villa F, Sanz-Julve ML, Crespo-Leiro M, Segovia J, Lopez-Granados A, Martinez-Dolz L, Mirabet S, Escribano P, Diaz-Molina B, Farrero M, Blasco T. Gonzalez-Vilchez F, et al. Among authors: blasco t. Int J Cardiol. 2014 Jan 15;171(1):15-23. doi: 10.1016/j.ijcard.2013.11.036. Epub 2013 Nov 23. Int J Cardiol. 2014. PMID: 24309084
Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry.
Crespo-Leiro MG, Alonso-Pulpón L, Arizón JM, Almenar L, Delgado JF, Palomo J, Manito N, Rábago G, Lage E, Diaz B, Roig E, Pascual D, Blasco T, de la Fuente L, Campreciós M, Vázquez de Prada JA, Muñiz J. Crespo-Leiro MG, et al. Among authors: blasco t. J Heart Lung Transplant. 2007 Nov;26(11):1105-9. doi: 10.1016/j.healun.2007.08.010. J Heart Lung Transplant. 2007. PMID: 18022075
Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study.
Delgado JF, Manito N, Almenar L, Crespo-Leiro M, Roig E, Segovia J, Vázquez de Prada JA, Lage E, Palomo J, Campreciós M, Arizón JM, Rodríguez-Lambert JL, Blasco T, de la Fuente L, Pascual D, Rábago G. Delgado JF, et al. Among authors: blasco t. Transpl Infect Dis. 2011 Apr;13(2):136-44. doi: 10.1111/j.1399-3062.2010.00573.x. Epub 2010 Oct 5. Transpl Infect Dis. 2011. PMID: 21040280
Steroid use in heart transplant patients in Spain in the current era: a multicenter survey.
Crespo-Leiro M, Delgado J, Almenar L, Arizón JM, Blasco T, Brossa V, De la Fuente L, Díaz B, Fernández-Yañez J, Garrido IP, Gómez Bueno M, González Vílchez F, Lage E, López López L, Mirabet S, Pérez-Villa F, Pulpón LA, Roig E, Vázquez de Prada JA. Crespo-Leiro M, et al. Among authors: blasco t. Transplant Proc. 2009 Jul-Aug;41(6):2244-6. doi: 10.1016/j.transproceed.2009.06.081. Transplant Proc. 2009. PMID: 19715887
74 results